STAT+: Why these health tech leaders are making a risky bet, openly backing Trump or Harris
Silicon Valley startup founders and venture capital investors are picking a side in this year’s…
Category: venture capital
Listen: VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a…
STAT+: Former Biden White House health official joins Flagship Pioneering
WASHINGTON — Raj Panjabi has made a career out of taking on some of public…
STAT+: Dental AI startup raises $30 million, including from Mark Zuckerberg’s dad
As the AI race in dentistry grows more heated, a startup called Perceptive is aiming…
STAT+: Startup Q Bio raises $27 million to build its own full-body scanner
A prevention-focused co-founded by the head of a Stanford research lab is making an expensive…
STAT+: Data privacy startup raises $30 million, to ease health care providers’ regulatory burden
Federal guidance restricting hospital websites’ use of third-party trackers along with the proliferation of direct-to-consumer…
STAT+: A cancer care startup is making a new bet with payers and providers: only pay if it works
A cancer care navigation startup has raised $95 million from prominent tech investors to help…
STAT+: AI leads the way as health tech funding inches toward a post-pandemic stability
Funding for health tech startups in the first half of 2024 remained far below the…
STAT+: Freespira bets on slow and steady, amid spectacular digital health collapses
Many digital health companies have crashed and burned after promising investors speedy adoption and huge…
STAT+: Venture capitalist Bob Kocher on generative AI startups, Change Healthcare cyberattack
SAN FRANCISCO — Health tech investor Bob Kocher has seen some bad AI-related startup pitches…
STAT+: Transcarent, Glen Tullman’s health tech unicorn, raises $126 million
Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman,…
Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
Listen: VC turmoil, GLP-1 competition, & the war on recovery
Why are addiction treatments so hard to get? Can small companies compete in obesity? And…
Q&A: A biotech VC leader shares her next big bets
Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners,…
STAT+: RayzeBio co-founder, industry veterans launch new biotech VC with $310 million
Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are…
STAT+: General Catalyst wants to take over a safety-net health system in Akron. The city has questions
General Catalysts’s grand vision for a venture capital-owned hospital system seamlessly blending AI and tech…
Listen: The plight of the VC, Gilead’s latest setback, & more M&A
Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to…
STAT+: As biotech VCs struggle to raise money, some debate whether the worst is over
Over the last year or two, something curious has started occurring in the conference rooms…
STAT+: Physician buy-in will make or break VC firm General Catalyst’s bold hospital deal
It makes sense in theory for hospitals and startups to strike deals. Not only would…
General Catalyst to buy Ohio-based health system Summa Health
Venture capital firm General Catalyst has agreed to acquire Ohio-based nonprofit health system Summa Health…
STAT+: Former Sage executives join biotech VC Cure Ventures
Cure Ventures, a Boston-based venture capital firm founded in 2021 by a trio of veteran…
STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference
Nonprofit hospitals often get overshadowed at the J.P. Morgan Healthcare Conference, the health care industry’s…
STAT Virtual Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: How the CEO of the largest medical device accelerator molds medtech startups
If Paul Grand weren’t the CEO of MedTech Innovator, the largest medical device accelerator in…
STAT+: Venture capitalists want to own hospitals. Can they do better than private equity?
General Catalyst’s plan to take over a hospital in the coming months could be the…
Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise
How do cancer drugs work? What makes biotech stocks go up? And why are venture…
STAT+: Health tech investors are getting selective. Expect slow growth, consolidation
Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to…
STAT+: Venture capital firm General Catalyst wants to buy a health system
Venture firms, convinced they’re jumpstarting the world’s most helpful tech products, have struggled mightily to…
Are biotech VCs headed for better times? In one firm’s success, lessons for turning crisis into profit
This article is adapted from STAT’s latest report, “2023 Update: ranking biotech’s top venture capital…
ARCH Venture Partners rises to the top of STAT’s 2023 biotech VC rankings
This article is adapted from the 2023 edition of STAT’s annual report, “Ranking biotech’s top…
STAT+: Westlake Village, a West Coast VC firm, raises $450 million fund
Westlake Village BioPartners, a West Coast biotech venture capital firm founded five years ago by…
STAT+: One of biotech’s biggest financiers launches small-molecule startup, in spite of IRA’s looming shadow
It’s been nearly a year since Congress passed the Inflation Reduction Act, raising a chorus…
Opinion: The lesson biotech absolutely should not take from Silicon Valley Bank’s failure
As a five-time biotech CEO, I’ve guided my companies through recessions, supply chain disruptions, Wall…
STAT+: KKR veteran sets records with $3.9 billion health care fund
The former head of health care investing at private equity giant KKR has set records…
Town Hall Ventures’ Andy Slavitt on how to invest in Medicaid and health tech
SAN FRANCISCO — Part of Andy Slavitt’s core mission at Town Hall Ventures is proving…
STAT+: Focused exclusively on life sciences, three top investors set out on their own
Almost a year ago, three top investors at Lux Capital and Obvious Ventures announced they…
STAT+: Boom and bust: Whose biotech VC assets have grown and shrunk the most?
Money has gushed into the biotech industry over the last couple of years, as the…
Opinion: Why the U.S. needs a public benefit biopharma industry
The biopharma industry is failing Americans, economically and medically. U.S. biotechnology and pharmaceutical companies, like…
Illumina’s $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Is Illumina a victim of its own success? What makes the FDA change its mind?…
STAT+: Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight
At the start of 2021, blue-chip biotech investor ARCH Venture Partners and a relatively unknown…
Fauci’s non-retirement, grading biotech VCs, & a bellwether IPO
Are we getting Covid-19 boosters wrong? Which venture capitalists are missing their marks? And what’s…
STAT+: OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking
Noted biotech investment firm OrbiMed slid from first place to 14th in STAT’s latest annual…
STAT+: Private equity giant Carlyle to acquire biotech venture capital firm Abingworth
The Carlyle Group will acquire Abingworth, one of biotech’s oldest venture capital groups, it announced…
STAT+ Conversations: Ranking biotech’s top venture capital firms
Editor’s note: A live stream of the conversation will be embedded above at 1 p.m….